Current Concepts in Probiotic Safety and Efficacy
Open accessThe DOI matches its Crossref record; 159 of the 184 references it cites were found in a registry or an index, and 18 are not checked yet; 108 of the 180 sources its claims cite were checked for support.
Abstract
This review summarizes current knowledge on the efficacy and safety of probiotics, analyzes limitations in clinical safety reporting, and compares regulatory frameworks governing the use of probiotics as dietary supplements, medicinal products, and live biotherapeutics. Particular attention is given to new genomic and computational approaches to safety assessment. Overall, the review emphasizes the need for coordinated regulation, rigorous clinical evidence, and integrated, modern safety assessment strategies to support the responsible expansion of probiotic use.
Verified 2026-11-20 · 18 references not checked yet
Overview
CoChat Summary
## TL;DR
This review argues that probiotics are generally safe for healthy people, but their safety and efficacy are highly strain-, dose-, host-, and context-dependent, with rare but serious harms reported in vulnerable groups. It also emphasizes that next-generation probiotics need stronger genomic, phenotypic, clinical, and regulatory scrutiny, alongside harmonized standards.
## Key findings
- Probiotics are “generally safe” for healthy individuals, but rare clinically significant adverse events have been reported, including bacteremia and endocarditis, especially in people with implanted devices, impaired barrier function, severe comorbidities, immunodeficiency, or critical illness.
- The review states that adverse-event data are incomplete: it says the true incidence of probiotic-associated infections is unknown because of lack of systematic reporting and weak post-market harm detection, and that most side effects are described in individual case reports rather than randomized trials.
- Clinical safety evidence is heterogeneous: the text notes 2 randomized controlled trials, 7 systematic reviews (including case reports), and 1 case report among the cited safety literature, with populations spanning healthy adults, mixed groups, and high-risk patients.
- A cited analysis of 622 randomized clinical studies found no statistically significant increase in relative risk for total adverse events, including serious ones, with short-term probiotic use versus controls; another report described 93 serious infections with a 15% mortality rate, including fungemia (37.6%), sepsis (31.2%), bacteremia (20.4%), endocarditis, and abscesses.
- Safety assessment should be strain-specific and multi-level: strain identification, phenotypic antimicrobial susceptibility testing, whole-genome sequencing, in vitro assays, preclinical models, and clinical trials/meta-analyses all contribute, while AI/computational tools are described as supportive but still preliminary/experimental.
## Methods
- Narrative review of current concepts in probiotic safety, efficacy, regulation, and computational assessment; the abstract states it “summarizes current knowledge,” analyzes limitations in clinical safety reporting, and compares regulatory frameworks.
- The paper draws on published literature and regulatory documents, including cited safety studies and frameworks from EFSA, FDA, FAO/WHO, and Russian regulations.
- Main analysis is qualitative synthesis: it contrasts traditional probiotics, next-generation probiotics, and live biotherapeutic products; reviews safety risks, reporting limitations, and genomic/computational screening approaches.
## Limitations
- The paper states that clinical safety reporting is limited by “lack of systematic reporting on adverse effects” and ineffective post-registration harm detection.
- It also states that many studies are heterogeneous in design, endpoints, strain identification, dosing, formulations, and populations, which reduces comparability and reproducibility.
- Evidence for AI/computational approaches is still preliminary and many predictions require external validation and biological confirmation; this is stated in the paper.
- Evident from the text: the review relies on narrative synthesis rather than a single new experimental dataset, so its conclusions depend on the quality and consistency of the underlying literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
66 Valid · 7 Not valid · 42 Not checked · 71 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Recent studies have linked probiotic-induced cytokine production, such as interleukins IL-1β, IL-6, tumor necrosis factor TNF-α, and interferons, to excessive immune reactions that can lead to autoimmune disorders or inflammation [12,86].”
§ Current Concepts in Probiotic Safety and Efficacy > 3. Safety, Toxicity and Other Risks Associated with Probiotics
What the sources say
- Disputedcites [12] Pyo Y. Kwon K.H. Jung Y.J. Probiotic functions in fermented foods: Anti-viral, immunomodulatory, and anti-cancer benefits Foods 2024 13 2386 10.3390/foods13152386 39123577 PMC11311591 sourceExperimental — accuracy not yet measured
Section 3, “Mechanisms of Health Benefits of Fermented Foods” (page unavailable), says probiotics downregulate pro-inflammatory cytokines and prevent inflammatory events—the opposite of the claimed link to excessive inflammation. Sections 4 and 5 likewise describe reductions in inflammatory factors, including TNF-α, interferon-γ, and IL-1β. The cited paper does not link probiotic-induced cytokine production to autoimmune disorders. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [86] Ashraf R. Vasiljevic T. Day S.L. Smith S.C. Donkor O.N. Lactic acid bacteria and probiotic organisms induce different cytokine profile and regulatory T cells mechanisms J. Funct. Foods 2014 6 395 409 10.1016/j.jff.2013.11.006 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although probiotics are generally safe for healthy individuals, rare but clinically significant infectious events, including bacteremia and endocarditis, have been reported, particularly in patients with implanted devices, impaired barrier function, or severe comorbidities [63].”
§ Current Concepts in Probiotic Safety and Efficacy > 3. Safety, Toxicity and Other Risks Associated with Probiotics
What the sources say
- Supportedcites [63] Doron S. Snydman D.R. Risk and safety of probiotics Clin. Infect. Dis. 2015 60 S129 S134 10.1093/cid/civ085 25922398 PMC4490230 source
The Systemic Infections discussion (indexed as Abstract; page unavailable) reports probiotic-associated bacteremia and endocarditis, including bacteremia in patients with central venous catheters. Table 2 (also indexed as Abstract) identifies valve replacements, bowel-wall translocation risks, and immunosuppression as potential risk factors; the cited case reports include patients with substantial comorbidities. (LLM, conf=0.89)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In contrast, studies involving mixed or high-risk populations, including patients receiving parenteral nutrition, those in intensive care, or patients with cancer, describe rare but serious adverse events in detail [73].”
§ Current Concepts in Probiotic Safety and Efficacy > 3. Safety, Toxicity and Other Risks Associated with Probiotics
What the sources say
- Supportedcites [73] Whelan K. Myers C.E. Safety of probiotics in patients receiving nutritional support: A systematic review of case reports, randomized controlled trials, and nonrandomized trials Am. J. Clin. Nutr. 2010 91 687 703 10.3945/ajcn.2009.28759 20089732 source
The Discussion reports 32 probiotic infections among patients receiving enteral or parenteral nutritional support, against 4,131 probiotic recipients in clinical trials. The case-report findings describe bacteremia and fungemia, including deaths; the paper also discusses ICU patients and cites a case of fungemia in a patient with head and neck cancer. These findings support the characterization of rare but serious adverse events in mixed or high-risk groups. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additional risks arise from strain-specific metabolic activity, such as the production of D-lactate or biogenic amines, which justifies targeted biochemical screening during the development phase [64,65].”
§ Current Concepts in Probiotic Safety and Efficacy > 3. Safety, Toxicity and Other Risks Associated with Probiotics
What the sources say
- Partly supportedcites [64] Rao S.S.C. Yu S. Tetangco E.P. Yan Y. Probiotics can cause D-lactic acidosis and brain fogginess: Reply to Quigley et al Clin. Transl. Gastroenterol. 2018 9 e207 10.1038/s41424-018-0077-5 PMC6240559 30449886 sourceExperimental — accuracy not yet measured
The reply states that probiotic species produce different amounts of D-lactate and that D-lactate production may contribute to brain fogginess (main text, points 3 and 7; page unavailable). It does not discuss biogenic amines or recommend targeted biochemical screening during development. It also says the underlying study was not designed to determine which probiotic or its contents was safer (point 5). (LLM, conf=0.88)
- Partly supportedcites [65] Barbieri F. Tofalo R. Suzzi G. Biogenic amine production by lactic acid bacteria: A review Foods 2019 8 17 10.3390/foods8010017 30621071 PMC6351943 sourceExperimental — accuracy not yet measured
The Toxicity section says biogenic amines can cause adverse effects and that the ability to produce them is generally strain-specific. The Conclusions recommend selecting strains that cannot produce them. These passages support the biogenic-amine risk and screening rationale, but our copy does not substantiate the D-lactate example. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The identification of mobile antimicrobial resistance genes and their potential impact on intestinal resistance also requires whole-genome sequencing and detailed characterization of antibiotic resistance genes [42,66,67,68].”
§ Current Concepts in Probiotic Safety and Efficacy > 3. Safety, Toxicity and Other Risks Associated with Probiotics
What the sources say
- Not matchedcites [42] FDA Microorganisms & Microbial-Derived Ingredients Used in Food. FDA, 2018 Available online: https://www.fda.gov/food/generally-recognized-safe-gras/microorganisms-microbial-derived-ingredients-used-food-partial-list (accessed on 22 December 2025)
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [66] Montassier E. Valdés-Mas R. Batard E. Zmora N. Dori-Bachash M. Suez J. Elinav E. Probiotics impact the antibiotic resistance gene reservoir along the human GI tract in a person-specific and antibiotic-dependent manner Nat. Microbiol. 2021 6 1361 1372 10.1038/s41564-021-00920-0 34226711 PMC8318886 sourceExperimental — accuracy not yet measured
The Methods describe shotgun sequencing and detailed ARG and mobile-genetic-element profiling. The Results assess potential horizontal transfer, but the Discussion says further studies are needed to prove transfer and resulting resistance. The paper therefore supports the value of this characterization, not the claim that whole-genome sequencing is required to identify mobile ARGs or establish their impact on intestinal resistance. (LLM, conf=0.83)
- Partly supportedcites [67] Papp M. Solymosi N. Review and comparison of antimicrobial resistance gene databases Antibiotics 2022 11 339 10.3390/antibiotics11030339 35326803 PMC8944830 sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says genome sequencing is commonly used in antimicrobial-resistance surveillance and that tools and databases analyze resistance genes in bacterial genomes and metagenomic samples. It also discusses genes with potential mobilization properties. It does not say whole-genome sequencing is required to identify mobile genes or assess their impact on intestinal resistance; the only intestinal-resistome match is a reference title. (LLM, conf=0.85)
- Partly supportedcites [68] Karnachuk O.V. Beletsky A.V. Rakitin A.L. Ikkert O.P. Avakyan M.R. Zyusman V.S. Mardanov A.V. Ravin N.V. Antibiotic-resistant Desulfovibrio produces H2S from supplements for animal farming Microorganisms 2023 11 838 10.3390/microorganisms11040838 37110261 PMC10146906 sourceExperimental — accuracy not yet measured
Methods §2.2 describes sequencing the L2 genome, and Results §3.3 uses that genome to identify and characterize resistance genes on a plasmid and chromosome. The Discussion §4 links those genes to potential lateral transfer, but the paper does not establish that whole-genome sequencing is required in general or measure an impact on intestinal resistance. Page numbers are unavailable in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
107 more claims · 48 with their cited sources checked
Create a free account to see all 186 claims and to verify the 6 references still open.
- It may state two separate claims as one. 61
- Probably not a substantial claim. 21
Citations
Cites
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592 · cited 2×
“…experimental and must undergo rigorous external validation and biological confirmation before they can be considered by regulators, highlighting that computational methods complement existing safety assessments based on standardized phenotypic testing and strain-level documentation [151,153,167].”
CARD 2020: Antibiotic Resistome Surveillance with the Comprehensive Antibiotic Resistance Database
Alcock, B. P., Raphenya, A. R., Lau, T. T. Y., Tsang, K. K., Bouchard, M., Edalatmand, A., Huynh, W., Nguyen, A.-L. V., Cheng, A. A., Liu, S., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz935 · Cited by 3,202
Mechanisms of Antibiotic Resistance
Munita, J. M., & Arias, C. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0016-2015 · Cited by 2,782
Salminen, S., Collado, M. C., Endo, A., Hill, C., Lebeer, S., Quigley, E. M. M., Sanders, M. E., Shamir, R., Swann, J. R., Szajewska, H., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00440-6 · Cited by 2,488 · cited 3×
“The use of dead cells in postbiotics eliminates the problem of fluctuations in quantitative composition during shelf life and is a good alternative to other groups [25,27].”
Probiotics and prebiotics in intestinal health and disease: from biology to the clinic
Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R., & Rastall, R. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0173-3 · Cited by 2,059 · cited 3×
“…experimental and must undergo rigorous external validation and biological confirmation before they can be considered by regulators, highlighting that computational methods complement existing safety assessments based on standardized phenotypic testing and strain-level documentation [151,153,167].”
Mechanisms of action of probiotics
Plaza-Diaz, J., Ruiz-Ojeda, F. J., Gil-Campos, M., & Gil, A. (2019) · Advances in Nutrition · doi:10.1093/advances/nmy063 · Cited by 1,423
Human gut microbiome: Hopes, threats and promises
Cani, P. D. (2018) · Gut · doi:10.1136/gutjnl-2018-316723 · Cited by 1,386 · cited 1×
“…are crucial for non-traditional probiotic candidates derived from gut commensals that lack a long history of safe use—such as Akkermansia , Faecalibacterium , Bacteroides , and Clostridium species—where in silico analyses complement phenotypic testing to accelerate safe development [153,162].”
Metabolic syndrome: pathophysiology, management, and modulation by natural compounds
Rochlani, Y., Pothineni, N. V., Kovelamudi, S., & Mehta, J. L. (2017) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944717711379 · Cited by 1,097 · cited 1×
“…disruption, high blood pressure, liver and kidney dysfunction, as well as excess body weight, abdominal obesity, and/or insulin resistance) [106], which is often associated with an increased risk of cardiovascular diseases and type 2 diabetes [107], and insulin resistance of various…”
Guidance on the characterisation of microorganisms used as feed additives or as production organisms
(FEEDAP), E. P. O. A. A. P. O. S. U. I. A. F., Rychen, G., Aquilina, G., Azimonti, G., Bampidis, V., Bastos, M. D. L., Bories, G., Chesson, A., Cocconcelli, P. S., Flachowsky, G., et al. (2018) · EFSA Journal · doi:10.2903/j.efsa.2018.5206 · Cited by 1,009
Next-generation probiotics: the spectrum from probiotics to live biotherapeutics
O’Toole, P. W., Marchesi, J. R., & Hill, C. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.57 · Cited by 971
Doron, S., & Snydman, D. R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ085 · Cited by 942 · cited 3×
“However, in the same year, Doron et al. (2015) conducted an analysis based solely on traditional literature review methods based on the results of 622 probiotic safety studies [63].”
Dunne, C., O’Mahony, L., Murphy, L., Thornton, G., Morrissey, D., O’Halloran, S., Feeney, M., Flynn, S., Fitzgerald, G., Daly, C., et al. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/73.2.386s · Cited by 922 · cited 1×
“While they do not prove in vivo efficacy, they provide key baseline data on function and safety, enabling the identification of priority strains for more in-depth studies [148].”
Demonstration of safety of probiotics—A review
Salminen, S. (1998) · International Journal of Food Microbiology · doi:10.1016/s0168-1605(98)00128-7 · Cited by 884 · cited 2×
“In vitro tests should help identify antibiotic resistance, hemolytic activity, and other important strain parameters [145,146], whereas in vivo studies should be conducted using animal models with weakened immune systems to more accurately model potential risks in vulnerable populations [75,147].”
Safety assessment of probiotics for human use
Sanders, M. E., Akkermans, L. M. A., Haller, D., Hammerman, C., Heimbach, J. T., Hörmannsperger, G., & Huys, G. (2010) · Gut Microbes · doi:10.4161/gmic.1.3.12127 · Cited by 816 · cited 6×
“In this context, conducting preclinical safety evaluations for each individual probiotic strain before its use in humans is crucial [19,144].”
InfluentialTerpou, A., Papadaki, A., Lappa, I., Kachrimanidou, V., Bosnea, L., & Kopsahelis, N. (2019) · Nutrients · doi:10.3390/nu11071591 · Cited by 779 · cited 1×
“Administration form also influences probiotic survival: some formulations provide better protection from gastric acidity and ensure higher strain viability at the site of action [138].”
Mechanisms of probiotic actions – A review
Oelschlaeger, T. A. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2009.08.005 · Cited by 719 · cited 2×
“The mechanism of action is determined by the ability of probiotics to act in three general modes: positive effect on barrier function, immune modulation, and metabolite production [13].”
Florensa, A. F., Kaas, R. S., Clausen, P. T. L. C., Aytan-Aktug, D., & Aarestrup, F. M. (2022) · Microbial Genomics · doi:10.1099/mgen.0.000748 · Cited by 695 · cited 2×
“In contrast, CARD and ResFinder use carefully curated databases to identify known antibiotic resistance genes, providing clear results but may fail to detect novel, unusual, or modulated resistance mechanisms [67,152,167,168].”
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
Goldenberg, J. Z., Yap, C., Lytvyn, L., Lo, C. K.-F., Beardsley, J., Mertz, D., & Johnston, B. C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006095.pub4 · Cited by 550 · cited 1×
“Such disturbances in gastrointestinal activity include vomiting, cramps, bloating, nausea, diarrhea, thirst, and taste disturbances that occur with the use of pro-biotics [98,99].”
Probiotics: determinants of survival and growth in the gut
Bezkorovainy, A. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/73.2.399s · Cited by 533 · cited 1×
“For example, the survival rate of bacteria during passage through the stomach and interaction with bile salts ranges from 20% to 40% [18], and of the 10 8 CFU of orally ingested lactobacilli, only 10 7 are found in the intestines [7].”
Biogenic Amine Production by Lactic Acid Bacteria: A Review
Barbieri, F., Montanari, C., Gardini, F., & Tabanelli, G. (2019) · Foods · doi:10.3390/foods8010017 · Cited by 528 · cited 2×
“Toxicology predictions, including genome-based hazard forecasts and developing machine-learning models, are being researched to anticipate adverse characteristics and reduce dependence on extensive in vivo testing, despite their application to probiotics being at a preliminary stage [65,157].”
Emerging issues in probiotic safety: 2023 perspectives
Merenstein, D., Pot, B., Leyer, G., Ouwehand, A. C., Preidis, G. A., Elkins, C. A., Hill, C., Lewis, Z. T., Shane, A. L., Zmora, N., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185034 · Cited by 481 · cited 6×
“Higher CFU doses, while potentially beneficial for increased efficacy, may increase the likelihood of gastrointestinal upset or infections in susceptible populations [20].”
Influential(EFSA), E. F. S. A. (2007) · EFSA Journal · doi:10.2903/j.efsa.2007.587 · Cited by 479
Antibiotic resistance in non-enterococcal lactic acid bacteria and bifidobacteria
Ammor, M. S., Belén Flórez, A., & Mayo, B. (2007) · Food Microbiology · doi:10.1016/j.fm.2006.11.001 · Cited by 460 · cited 1×
“Acquired resistance can arise either through the addition of genes (e.g., by obtaining exogenous DNA) or through mutation of one’s own genes [127,128].”
Probiotic supplements might not be universally-effective and safe: A review
Kothari, D., Patel, S., & Kim, S.-K. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.104 · Cited by 445 · cited 1×
“Therefore, caution is required when using probiotics in autoimmune diseases, particularly in individuals at higher risk [88].”
Mechanisms of antibiotic resistance
Munita, J. M., & Arias, C. A. (2016) · Virulence Mechanisms of Bacterial Pathogens · doi:10.1128/9781555819286.ch17 · Cited by 421
Johnston, B. C., Ma, S. S. Y., Goldenberg, J. Z., Thorlund, K., Vandvik, P. O., Loeb, M., & Guyatt, G. H. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-12-201212180-00563 · Cited by 367
Genus-Wide Assessment of Antibiotic Resistance in Lactobacillus spp
Campedelli, I., Mathur, H., Salvetti, E., Clarke, S., Rea, M. C., Torriani, S., Ross, R. P., Hill, C., & O’Toole, P. W. (2019) · Applied and Environmental Microbiology · doi:10.1128/aem.01738-18 · Cited by 343 · cited 4×
“…as whole genome sequencing and bioinformatics analysis are increasingly being included in probiotic regulatory dossiers as supporting evidence for strain characterization and safety, provided that the methods are transparent, reproducible, and interpretable alongside phenotypic data [31,132,133].”
InfluentialLive biotherapeutic products: The importance of a defined regulatory framework
Cordaillat-Simmons, M., Rouanet, A., & Pot, B. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0437-6 · Cited by 328
Prebiotics and Probiotics Science and Technology
(2009) · doi:10.1007/978-0-387-79058-9 · Cited by 325
Recycling Metchnikoff: Probiotics, the Intestinal Microbiome and the Quest for Long Life
Mackowiak, P. A. (2013) · Frontiers in Public Health · doi:10.3389/fpubh.2013.00052 · Cited by 294 · cited 1×
“Mechnikov’s early 20th-century theory suggested that Bulgarian yogurt could extend life by suppressing harmful intestinal fermentation, a concept that gained wider medical support in the mid-1990s [3].”
(BIOHAZ), E. P. O. B. H., Koutsoumanis, K., Allende, A., Alvarez‐Ordóñez, A., Bolton, D., Bover‐Cid, S., Chemaly, M., Davies, R., De Cesare, A., Hilbert, F., et al. (2020) · EFSA Journal · doi:10.2903/j.efsa.2020.5966 · Cited by 294
Montassier, E., Valdés-Mas, R., Batard, E., Zmora, N., Dori-Bachash, M., Suez, J., & Elinav, E. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00920-0 · Cited by 256 · cited 3×
“The identification of mobile antimicrobial resistance genes and their potential impact on intestinal resistance also requires whole-genome sequencing and detailed characterization of antibiotic resistance genes [42,66–68].”
A comprehensive review of probiotics and human health-current prospective and applications
Sarita, B., Samadhan, D., Hassan, M. Z., & Kovaleva, E. G. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1487641 · Cited by 250 · cited 1×
“…, Leuconos-toc , Propionibacterium freudenreichii , Bacillus , Pediococcus (QPS List (EU) or GRAS (FDA)— confirm species-level history of safe use) and less commonly used Enterococcus faecium (QPS status with qualifications) and Saccharomyces cerevisiae (QPS List (EU)/GRAS (FDA)) [16,17].”
Safety of probiotics used to reduce risk and prevent or treat disease.
(2011) · PubMed Central · Cited by 242
Abouelela, M. E., & Helmy, Y. A. (2024) · Microorganisms · doi:10.3390/microorganisms12030430 · Cited by 238 · cited 3×
“NGPs, as well as biotherapeutic drugs (LBP) or medicinal products, must undergo pharmaceutical clinical trials and studies of their pharmacokinetics and pharmacodynamics with the wide use of new technologies such as genetic sequencing and bioinformatics [22].”
(EFSA), E. F. S. A. (2021) · EFSA Journal · doi:10.2903/j.efsa.2021.6506 · Cited by 222 · cited 1×
“…are of significant importance for food-grade probiotics, whereas assessment is conducted according to drug or biological standards requiring preclinical safety, controlled efficacy trials, compliance with GMP standards, and enhanced genomics and pharmacovigilance data for therapeutic LBPs [29,32].”
The promise of the gut microbiome as part of individualized treatment strategies
Schupack, D. A., Mars, R. A. T., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00499-1 · Cited by 217 · cited 1×
“Clinical outcomes vary widely because host genetics, baseline microbiota, diet, medications, and comorbidities modulate response and susceptibility, which explains the heterogeneous results across studies [15,114,115].”
Effects of Probiotics on Metabolic Syndrome: A Systematic Review of Randomized Clinical Trials
Tenorio-Jiménez, C., Martínez-Ramírez, M. J., Gil, Á., & Gómez-Llorente, C. (2020) · Nutrients · doi:10.3390/nu12010124 · Cited by 206 · cited 5×
“The clinical implications of this issue are unclear [15,136].”
InfluentialDeepMicro: Deep representation learning for disease prediction based on microbiome data
Oh, M., & Zhang, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-63159-5 · Cited by 190 · cited 3×
“In contrast, CARD and ResFinder use carefully curated databases to identify known antibiotic resistance genes, providing clear results but may fail to detect novel, unusual, or modulated resistance mechanisms [67,152,167,168].”
Next-generation probiotics: the upcoming biotherapeutics
Al-Fakhrany, O. M., & Elekhnawy, E. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09398-5 · Cited by 188
The developing gut microbiota and its consequences for health
Butel, M.-J., Waligora-Dupriet, A.-J., & Wydau-Dematteis, S. (2018) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174418000119 · Cited by 182 · cited 1×
“Disrupted microbial colonization in early childhood is associated with an increased risk of food allergy [96], but studies of the use of probiotics in cow’s milk allergy remain inconclusive due to heterogeneity in host health status and genetic background [97].”
Comprehensive approaches for assessing the safety of probiotic bacteria
Pradhan, D., Mallappa, R. H., & Grover, S. (2020) · Food Control · doi:10.1016/j.foodcont.2019.106872 · Cited by 179 · cited 1×
“In vitro tests should help identify antibiotic resistance, hemolytic activity, and other important strain parameters [145,146], whereas in vivo studies should be conducted using animal models with weakened immune systems to more accurately model potential risks in vulnerable populations [75,147].”
A critical review of antibiotic resistance in probiotic bacteria
Li, T., Teng, D., Mao, R., Hao, Y., Wang, X., & Wang, J. (2020) · Food Research International · doi:10.1016/j.foodres.2020.109571 · Cited by 172 · cited 1×
“The scientific literature contains numerous studies on this topic [87,126].”
van Reenen, C. A., & Dicks, L. M. T. (2011) · Archives of Microbiology · doi:10.1007/s00203-010-0668-3 · Cited by 167
Bafeta, A., Koh, M., Riveros, C., & Ravaud, P. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0343 · Cited by 162 · cited 1×
“This is due to the lack of systematic reporting on adverse effects during clinical trials and the inefficiency of existing mechanisms for detecting harm after probiotic product registration [78].”
Whelan, K., & Myers, C. E. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28759 · Cited by 161 · cited 1×
“In contrast, studies involving mixed or high-risk populations, including patients receiving parenteral nutrition, those in intensive care, or patients with cancer, describe rare but serious adverse events in detail [73].”
Reappraisal of probiotics’ safety in human
Sotoudegan, F., Daniali, M., Hassani, S., Nikfar, S., & Abdollahi, M. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.04.032 · Cited by 154 · cited 2×
“Probiotics are considered safe due to their composition and may also be suitable for most vulnerable populations, such as infants, the elderly, and those with weakened immune systems [28].”
Metabolic syndrome: Does it differ between women and men?
Rochlani, Y., Pothineni, N. V., & Mehta, J. L. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6593-6 · Cited by 152 · cited 1×
“The clinical implications of this issue are unclear [15,136].”
Probiotics as a biological detoxification tool of food chemical contamination: A review
Średnicka, P., Juszczuk‐Kubiak, E., Wójcicki, M., Akimowicz, M., & Roszko, M. Ł. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112306 · Cited by 148
Considerations for determining safety of probiotics: A USP perspective
Roe, A. L., Boyte, M.-E., Elkins, C. A., Goldman, V. S., Heimbach, J., Madden, E., Oketch-Rabah, H., Sanders, M. E., Sirois, J., & Smith, A. (2022) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2022.105266 · Cited by 136 · cited 2×
“…include accurate strain identification and traceability, comprehensive safety assessment (including whole-genome analysis for potential virulence and antibiotic resistance), proven efficacy for the intended use, and robust manufacturing controls to ensure product stability and purity [31–33].”
Spacova, I., Binda, S., ter Haar, J. A., Henoud, S., Legrain-Raspaud, S., Dekker, J., Espadaler-Mazo, J., Langella, P., Martín, R., Pane, M., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1272754 · Cited by 129 · cited 3×
“This means that they must undergo rigorous safety, efficacy, and quality testing similar to that applied to pharmaceuticals [29,30].”
Discovery and delivery strategies for engineered live biotherapeutic products
Heavey, M. K., Durmusoglu, D., Crook, N., & Anselmo, A. C. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2021.08.002 · Cited by 125 · cited 1×
“The intensive development of omics technologies and their application in microbiome research has significantly expanded the understanding of human microbiota, both as a whole and at the individual genomic level [4,5].”
Live Biotherapeutic Products, A Road Map for Safety Assessment
Rouanet, A., Bolca, S., Bru, A., Claes, I., Cvejic, H., Girgis, H., Harper, A., Lavergne, S. N., Mathys, S., Pane, M., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00237 · Cited by 120 · cited 2×
“Regulatory requirements for the characterization of antimicrobial resistance genes (AMR) in probiotics and biopharmaceuticals are set out in regulatory documents from regulatory bodies such as the EFSA, FDA, and FAO/WHO [34,124,125].”
Allen, S. J., Jordan, S., Storey, M., Thornton, C. A., Gravenor, M., Garaiova, I., Plummer, S. F., Wang, D., & Morgan, G. (2010) · The Journal of Nutrition · doi:10.3945/jn.109.117093 · Cited by 119 · cited 1×
“In such vulnerable patient groups, intestinal barrier dysfunction increases the risk of adverse effects from probiotics [81] and may contribute to infection development, which can subsequently lead to sepsis or inflammation [19].”
Safety aspects of next generation probiotics
Saarela, M. H. (2019) · Current Opinion in Food Science · doi:10.1016/j.cofs.2018.09.001 · Cited by 118 · cited 2×
“…of probiotics, NGPs (e.g., specifically commensal gut bacteria such as Bacteroides , Clostridium , and Akkermansia ), require greater safety consideration than traditional probiotics because they lack a “safe use history” and have a more “ambiguous” potential to cause infectious diseases [140].”
Probiotic safety—No guarantees
Cohen, P. A. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.5403 · Cited by 113 · cited 1×
“Despite the large number of clinical observations regarding the use of probiotics, accurate data on the incidence of infections associated with their use remain unknown [77].”
D’Urso, F., & Broccolo, F. (2024) · Applied Sciences · doi:10.3390/app14198627 · Cited by 112
Kumari, M., Singh, P., Nataraj, B. H., Kokkiligadda, A., Naithani, H., Azmal Ali, S., Behare, P. V., & Nagpal, R. (2021) · Food Research International · doi:10.1016/j.foodres.2021.110716 · Cited by 107 · cited 1×
“Additionally, safety should be evaluated through animal models of relevant diseases and human clinical trials [143].”
Probiotic viability–does it matter?
Lahtinen, S. J. (2012) · Microbial Ecology in Health & Disease · doi:10.3402/mehd.v23i0.18567 · Cited by 107 · cited 1×
“Viability is also important for probiotic safety, as non-viable strains may not provide beneficial health effects and may cause harm if improperly stored or managed [137].”
Magro, D. O., de Oliveira, L. M. R., Bernasconi, I., de Souza Ruela, M., Credidio, L., Barcelos, I. K., Leal, R. F., Ayrizono, M. D. L. S., Fagundes, J. J., Teixeira, L. D. B., et al. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-75 · Cited by 105 · cited 1×
“The possible transfer of antibiotic resistance genes from probiotic microorganisms to commensal pathogens within the gut flora is another aspect that raises concerns about the https://doi.org/10.3390/nu18040696 safety of probiotics [121].”
InfluentialCosta, R. L., Moreira, J., Lorenzo, A., & Lamas, C. C. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2394-3 · Cited by 105
Antibiotic resistance determinants in the interplay between food and gut microbiota
Devirgiliis, C., Barile, S., & Perozzi, G. (2011) · Genes & Nutrition · doi:10.1007/s12263-011-0226-x · Cited by 105 · cited 2×
“…in open ecosystems such as the gastrointestinal tract, intrinsic antimicrobial resistance is generally regarded as having a low potential of horizontal spread, whereas acquired resistance encoded by additional genes is considered to carry a substantially higher risk of lateral transfer [128,129].”
d'Ettorre, G., Rossi, G., Scagnolari, C., Andreotti, M., Giustini, N., Serafino, S., Schietroma, I., Scheri, G. C., Fard, S. N., Trinchieri, V., et al. (2017) · Immunity, Inflammation and Disease · doi:10.1002/iid3.160 · Cited by 104
How can probiotics and prebiotics impact mucosal immunity?
O'Flaherty, S., Saulnier, D., Pot, B., & Versalovic, J. (2010) · Gut Microbes · doi:10.4161/gmic.1.5.12924 · Cited by 103
Cholesterol-lowering effects of Lactobacillus species
Khare, A., & Gaur, S. (2020) · Current Microbiology · doi:10.1007/s00284-020-01903-w · Cited by 100 · cited 1×
“Species such as Bifidobacterium , Pediococcus , and Lactobacillus secrete this hydrolase, which deconjugates primary bile acids and reduces cholesterol reabsorption in the host’s body [102].”
Mobile antimicrobial resistance genes in probiotics
Tóth, A. G., Csabai, I., Judge, M. F., Maróti, G., Becsei, Á., Spisák, S., & Solymosi, N. (2021) · doi:10.1101/2021.05.04.442546 · Cited by 97 · cited 1×
“Risk categories for probiotics are associated with four interrelated factors: acquired antimicrobial resistance genes, virulence factors, translocation, and mobile or unstable genomic elements that allow horizontal gene transfer [43,44].”
Review and Comparison of Antimicrobial Resistance Gene Databases
Papp, M., & Solymosi, N. (2022) · doi:10.20944/preprints202202.0200.v1 · Cited by 97
Review and Comparison of Antimicrobial Resistance Gene Databases
Papp, M., & Solymosi, N. (2022) · Antibiotics · doi:10.3390/antibiotics11030339 · Cited by 96
The role of artificial intelligence in advancing food safety: A strategic path to zero contamination
Naseem, S., & Rizwan, M. (2025) · Food Control · doi:10.1016/j.foodcont.2025.111292 · Cited by 88
Sachdeva, A., Tomar, T., Malik, T., Bains, A., & Karnwal, A. (2025) · Frontiers in Sustainable Food Systems · doi:10.3389/fsufs.2024.1523678 · Cited by 84 · cited 1×
“…and treating cardiovascular diseases, diabetes, and allergic diseases [8], regulating the state of the central nervous system through modulation of the “brain–gut” axis [9], performing detoxification functions [10], and exhibiting antimicrobial [11], antiviral, and antitumor properties [12].”
Safety evaluation of probiotics
O'Brien, J., Crittenden, R. G., Ouwehand, A. C., & Salminen, S. (1999) · Trends in Food Science & Technology · doi:10.1016/s0924-2244(00)00037-6 · Cited by 83
Dore, M. P., Bibbò, S., Fresi, G., Bassotti, G., & Pes, G. M. (2019) · Nutrients · doi:10.3390/nu11122913 · Cited by 83 · cited 1×
“A meta-analysis of nine controlled trials patients with inflammatory bowel disease showed higher AE risk with probiotics/synbiotics [111].”
Ağagündüz, D., Bingöl, F. G., Çelik, E., Cemali, Ö., Özenir, Ç., Özoğul, F., & Capasso, R. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03609-y · Cited by 82
Microbiome Therapeutics Innovation Group, & Barberio, D. (2024) · Frontiers in Microbiomes · doi:10.3389/frmbi.2024.1441290 · Cited by 82
Munblit, D., Treneva, M., Peroni, D., Colicino, S., Chow, L., Dissanayeke, S., Pampura, A., Boner, A., Geddes, D., Boyle, R., et al. (2017) · Nutrients · doi:10.3390/nu9060532 · Cited by 80
A case of D-lactic acid encephalopathy associated with use of probiotics
Munakata, S., Arakawa, C., Kohira, R., Fujita, Y., Fuchigami, T., & Mugishima, H. (2010) · Brain and Development · doi:10.1016/j.braindev.2009.09.024 · Cited by 78 · cited 1×
“For instance, Lactobacillus spp. is largely responsible for D-lactic acidosis development in patients with short bowel syndrome [100].”
Emerging pre-clinical safety assessments for potential probiotic strains: a review
Nataraj, B. H., Behare, P. V., Yadav, H., & Srivastava, A. K. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2197066 · Cited by 77 · cited 4×
“…the probiotic strain using genomic methods to identify potential virulence factors, antibiotic resistance genes, and other pathogenicity factors [82,144], metabolic activity [75], immune responses in terms of stimulation or suppression, especially in vulnerable populations such as children or…”
InfluentialRecent advances in AI-based toxicity prediction for drug discovery
Lee, H., Kim, J., Kim, J.-W., & Lee, Y. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1632046 · Cited by 76 · cited 1×
“Toxicology predictions, including genome-based hazard forecasts and developing machine-learning models, are being researched to anticipate adverse characteristics and reduce dependence on extensive in vivo testing, despite their application to probiotics being at a preliminary stage [65,157].”
Castro-López, C., García, H. S., Guadalupe Martínez-Ávila, G. C., González-Córdova, A. F., Vallejo-Cordoba, B., & Hernández-Mendoza, A. (2021) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2020.12.017 · Cited by 72
(BIOHAZ), E. P. O. B. H., Ricci, A., Allende, A., Bolton, D., Chemaly, M., Davies, R., Fernández Escámez, P. S., Girones, R., Koutsoumanis, K., Lindqvist, R., et al. (2018) · EFSA Journal · doi:10.2903/j.efsa.2018.5315 · Cited by 72
Cow’s Milk Allergy: Immunomodulation by Dietary Intervention
D’Auria, E., Salvatore, S., Pozzi, E., Mantegazza, C., Sartorio, M. U. A., Pensabene, L., Baldassarre, M. E., Agosti, M., Vandenplas, Y., & Zuccotti, G. (2019) · Nutrients · doi:10.3390/nu11061399 · Cited by 70 · cited 1×
“Disrupted microbial colonization in early childhood is associated with an increased risk of food allergy [96], but studies of the use of probiotics in cow’s milk allergy remain inconclusive due to heterogeneity in host health status and genetic background [97].”
Big Data Impacting Dynamic Food Safety Risk Management in the Food Chain
Donaghy, J. A., Danyluk, M. D., Ross, T., Krishna, B., & Farber, J. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.668196 · Cited by 67 · cited 1×
“Simultaneously, real-time monitoring technologies integrating bioinformatics with multi-omics and digital health data are starting to allow for the long-term tracking of probiotic strains and host responses, especially in translational and post-market settings [159,160].”
Probiotic Functions in Fermented Foods: Anti-Viral, Immunomodulatory, and Anti-Cancer Benefits
Pyo, Y., Kwon, K. H., & Jung, Y. J. (2024) · Foods · doi:10.3390/foods13152386 · Cited by 66 · cited 2×
“…and treating cardiovascular diseases, diabetes, and allergic diseases [8], regulating the state of the central nervous system through modulation of the “brain–gut” axis [9], performing detoxification functions [10], and exhibiting antimicrobial [11], antiviral, and antitumor properties [12].”
Tan‐Lim, C. S. C., Esteban‐Ipac, N. A. R., Recto, M. S. T., Castor, M. A. R., Casis‐Hao, R. J., & Nano, A. L. M. (2021) · Pediatric Allergy and Immunology · doi:10.1111/pai.13514 · Cited by 65
Jones, M. L., Martoni, C. J., Di Pietro, E., Simon, R. R., & Prakash, S. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.04.003 · Cited by 64 · cited 1×
“Probiotics and LBPs are generally well tolerated by healthy adult individuals [71].”
Han, X., Liu, Q., Li, Y., Zhang, M., Liu, K., Kwok, L.-Y., Zhang, H., & Zhang, W. (2025) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2025.104938 · Cited by 64 · cited 5×
“…genes and virulence factors at the genomic level); and prediction based on a machine learning model with the identification of specific tRNAs that distinguish safe probiotics against dangerous intestinal pathogens, which helps to carry out screening at an early stage [156,165,166].”
InfluentialKumar, M., Ghosh, M., & Ganguli, A. (2012) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-011-0866-4 · Cited by 63 · cited 1×
“…bacteria do not exhibit harmful biochemical properties for the host organism, such as β - glucosidase, α -chymotrypsin, β -glucuronidase, and N-acetyl-β -glucosaminidase activities, which are associated with intestinal diseases and can promote the formation of carcinogens and tumor promoters [105].”
Traditional Bulgarian Dairy Products: Ethnic Foods with Health Benefits
Petrova, P., Ivanov, I., Tsigoriyna, L., Valcheva, N., Vasileva, E., Parvanova-Mancheva, T., Arsov, A., & Petrov, K. (2021) · Microorganisms · doi:10.3390/microorganisms9030480 · Cited by 62 · cited 1×
“Various fermentation technologies involving different strains of lactic acid bacteria are used to improve the consumer properties of the valuable products obtained [1].”
Ashraf, R., Vasiljevic, T., Day, S. L., Smith, S. C., & Donkor, O. N. (2014) · Journal of Functional Foods · doi:10.1016/j.jff.2013.11.006 · Cited by 62 · cited 1×
“Recent studies have linked probiotic-induced cytokine production, such as interleukins IL-1 β , IL-6, tumor necrosis factor TNF-α , and interferons, to excessive immune reactions that can lead to autoimmune disorders or inflammation [12,86].”
Paquet, J.-C., Claus, S. P., Cordaillat‐Simmons, M., Mazier, W., Rawadi, G., Rinaldi, L., Elustondo, F., & Rouanet, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.716266 · Cited by 60 · cited 3×
“When planning and conducting clinical trials of new probiotic strains, it is also necessary to adhere to the requirements of regulatory bodies, maintaining close collaboration with them (Figure 2) [50].”
Asthma in the Precision Medicine Era: Biologics and Probiotics
Chiu, C.-J., & Huang, M.-T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094528 · Cited by 60
Dhondge, R. H., Agrawal, S., Patil, R., Kadu, A., & Kothari, M. (2024) · Cureus · doi:10.7759/cureus.67428 · Cited by 60
(BIOHAZ), E. P. O. B. H., Koutsoumanis, K., Allende, A., Álvarez‐Ordóñez, A., Bolton, D., Bover‐Cid, S., Chemaly, M., Davies, R., Hilbert, F., Lindqvist, R., et al. (2019) · EFSA Journal · doi:10.2903/j.efsa.2019.5555 · Cited by 59
Kundu, S., Kumar, S., & Bajaj, A. (2015) · IUBMB Life · doi:10.1002/iub.1399 · Cited by 56 · cited 1×
“Furthermore, excessive bile acid accumulation can lead to colon cancer development [104].”
Dickinson, A. (2010) · Fitoterapia · doi:10.1016/j.fitote.2010.09.001 · Cited by 52 · cited 1×
“According to the DSHEA, dietary supplements used since 1994 are permitted for inclusion in food products as ingredients [54].”
Liu, P. C., Yan, Y. K., Ma, Y. J., Wang, X. W., Geng, J., Wang, M. C., Wei, F. X., Zhang, Y. W., Xu, X. D., & Zhang, Y. C. (2017) · Gastroenterology Research and Practice · doi:10.1155/2017/6029075 · Cited by 49 · cited 3×
“Simultaneously, an analysis of the results of clinical studies provides a contradictory picture of the confirmed effects of probiotics [14,15].”
Senan, S., Prajapati, J. B., & Joshi, C. G. (2015) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-015-9199-1 · Cited by 46 · cited 2×
“For example, the high variability of biological datasets on different platforms for sequence determination causes problems with the reliability of the source data, which undoubtedly underestimates the accuracy of the AI model [154,172].”
Garg, V., Velumani, D., Lin, Y.-C., & Haye, A. (2024) · PharmaNutrition · doi:10.1016/j.phanu.2024.100423 · Cited by 44 · cited 2×
“This restriction leads to cautious labeling and limited marketing [39,60].”
InfluentialAccounting for the health risk of probiotics
Liu, X., Zhao, H., & Wong, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27908 · Cited by 44 · cited 7×
“The bottom line is that the results regarding probiotic use described in the scientific literature are irregular and vary significantly due to differences in probiotic types, their doses, and treatment regimens across studies [87].”
InfluentialProbiotic Development Strategy Centered on Stability and Regulatory Considerations
Kim, H., Haque, M. A., Razzak, M. A., Jang, M. J., Song, S., & Ku, S. (2026) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.70320 · Cited by 43 · cited 1×
“Efficacy and safety standards also vary, increasing costs and complicating worldwide regulatory compliance, which in turn leads to differences in regional market access [29,61].”
Probiotics and prebiotics: health claim substantiation
Salminen, S., & van Loveren, H. (2012) · Microbial Ecology in Health & Disease · doi:10.3402/mehd.v23i0.18568 · Cited by 43
Lactobacillus Species as Probiotics: Isolation Sources and Health Benefits
Al-Yami, A. M., Mousa, A. T. A., Al-Otaibi, S. A., & Khalifa, A. Y. Z. (2022) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.16.4.19 · Cited by 43
Lactobacilli: Legal Regulation and Prospects for New Generation Drugs
Yunes, R. А., Poluektova, E. U., Белкина, Т. В., & Даниленко, В. Н. (2022) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683822050179 · Cited by 42 · cited 4×
“For example, prebiotics are products that support the health of the host’s microbiota through modulatory properties but contain non-living food ingredients [4].”
InfluentialRadovanovic, M., Kekic, D., Gajic, I., Kabic, J., Jovicevic, M., Kekic, N., Opavski, N., & Ranin, L. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1054555 · Cited by 42 · cited 1×
“Horizontal gene transfer through mobile genetic elements can pose a significant threat to human health through the development of antimicrobial resistance (AMR) [66,130].”
Factors that influence clinical efficacy of live biotherapeutic products
Pot, B., & Vandenplas, Y. (2021) · European journal of medical research · doi:10.1186/s40001-021-00509-7 · Cited by 41 · cited 2×
“The dossier submission procedure is not sufficiently detailed in both cases [47].”
Safety Assessment of Probiotics
Lahtinen, S. J., Boyle, R. J., Margolles, A., Frias, R., & Gueimonde, M. (2009) · Prebiotics and Probiotics Science and Technology · doi:10.1007/978-0-387-79058-9_31 · Cited by 39 · cited 3×
“For example, wild strains of Lactobacillus and Bifidobacterium also contain antibiotic resistance genes that are similar to those found in probiotic isolates [101].”
InfluentialMikucka, A., Deptuła, A., Bogiel, T., Chmielarczyk, A., Nurczyńska, E., & Gospodarek-Komkowska, E. (2022) · Pathogens · doi:10.3390/pathogens11090977 · Cited by 38 · cited 5×
“…genomic methods to identify potential virulence factors, antibiotic resistance genes, and other pathogenicity factors [82,144], metabolic activity [75], immune responses in terms of stimulation or suppression, especially in vulnerable populations such as children or patients with autoimmune…”
InfluentialUnderstanding the Functionality of Probiotics on the Edge of Artificial Intelligence (AI) Era
Asar, R., Erenler, S., Devecioglu, D., Ispirli, H., Karbancioglu-Guler, F., Ozturk, H. I., & Dertli, E. (2025) · Fermentation · doi:10.3390/fermentation11050259 · Cited by 37 · cited 3×
“The growth of AI capabilities is fueling new fields, such as probiogenomics, where computational models are used to predict how a probiotic’s genome will interact with the host immune system or existing microbiota, ensuring stable colonization without side effects [164,169].”
Harnessing Artificial Intelligence to Safeguard Food Quality and Safety
Singh, D. (2025) · Journal of Food Protection · doi:10.1016/j.jfp.2025.100621 · Cited by 37 · cited 1×
“Simultaneously, real-time monitoring technologies integrating bioinformatics with multi-omics and digital health data are starting to allow for the long-term tracking of probiotic strains and host responses, especially in translational and post-market settings [159,160].”
Live biotherapeutic products and their regulatory framework in Italy and Europe.
Franciosa, G., Guida, S., Gomez, M. J., & von Hunolstein, C. (2023) · Annali dell Istituto Superiore di Sanità · doi:10.4415/ann_23_01_09 · Cited by 37
Mafe, A. N., Sharifi‐Rad, J., Călina, D. C., Ogunyemi, A. J., & Abiola, O. T. (2025) · Food Frontiers · doi:10.1002/fft2.70205 · Cited by 36 · cited 2×
“The development of reliable quality control measures for postbiotics, validated methods for analyzing active ingredients, and harmonization of international standards will help address these gaps [26].”
Genomic insights into antibiotic resistance and mobilome of lactic acid bacteria and bifidobacteria
Rozman, V., Mohar Lorbeg, P., Treven, P., Accetto, T., Janežič, S., Rupnik, M., & Bogovič Matijašić, B. (2023) · Life Science Alliance · doi:10.26508/lsa.202201637 · Cited by 36 · cited 4×
“…as whole genome sequencing and bioinformatics analysis are increasingly being included in probiotic regulatory dossiers as supporting evidence for strain characterization and safety, provided that the methods are transparent, reproducible, and interpretable alongside phenotypic data [31,132,133].”
InfluentialAI in microbiome‐related healthcare
Probul, N., Huang, Z., Saak, C. C., Baumbach, J., & List, M. (2024) · Microbial Biotechnology · doi:10.1111/1751-7915.70027 · Cited by 36 · cited 1×
“Despite their potential, AI-based forecasts still require careful experimental and clinical verification to ensure human safety due to the lack of a unified validation system for methods [173].”
Ivashkin, V. T., Maev, I. V., Abdulganieva, D. I., Alekseenko, S. A., Gorelov, A. V., Zakharova, I. N., Zolnikova, O. Y., Ivashkina, N. Y., Korochanskaya, N. V., Mammayev, S. N., et al. (2021) · Russian Journal of Gastroenterology, Hepatology, Coloproctology · doi:10.22416/1382-4376-2021-31-2-65-91 · Cited by 35
Zielińska, D., Sionek, B., & Kołożyn-Krajewska, D. (2018) · Diet, Microbiome and Health · doi:10.1016/b978-0-12-811440-7.00006-5 · Cited by 34 · cited 1×
“This finding is related to the disruption of the balance between the symbiotic gut microbiota and the immune system [80].”
Models for Gut-Mediated Horizontal Gene Transfer by Bacterial Plasmid Conjugation
Ott, L. C., & Mellata, M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.891548 · Cited by 32 · cited 1×
“In vitro and in model systems, experimental studies have shown plasmid conjugation between enterobacteria and Gram-positive recipients, including LAB [44,123].”
Probiotics and pharmabiotics: Alternative medicine or an evidence-based alternative?
Hill, C. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.2.10796 · Cited by 31 · cited 2×
“Since the FAO definition did not establish clear boundaries for distinguishing probiotics for use as food or medicinal products, later terms such as “pharmabiotics” [35] or “live biotherapeutic products (LBP)” [36] were proposed (Table 2).”
Tremblay, A., Fatani, A., Ford, A. L., Piano, A., Nagulesapillai, V., Auger, J., MacPherson, C. W., Christman, M. C., Tompkins, T. A., & Dahl, W. J. (2021) · Journal of Dietary Supplements · doi:10.1080/19390211.2020.1749751 · Cited by 31 · cited 1×
“Randomized studies involving up to 25 billion colony-forming units in healthy subjects did not show an increase in adverse events or laboratory abnormalities [72].”
Lalowski, P., & Zielińska, D. (2024) · Fermentation · doi:10.3390/fermentation10090444 · Cited by 30 · cited 1×
“Therefore, a thorough characterization of the strain is essential, encompassing whole-genome sequencing and the analysis of virulence factors, antibiotic resistance genes, and transferable genetic elements [142].”
Next-generation probiotics: Innovations in safety assessments
Hua, Z., Liu, S., Yang, G., Hou, X., & Fang, Y. (2025) · Current Opinion in Food Science · doi:10.1016/j.cofs.2024.101238 · Cited by 29 · cited 4×
“Unlike traditional probiotics, which are primarily aimed at improving gut health, NGPs are specifically developed for the treatment of specific diseases with targeted therapeutic effects [21].”
InfluentialNext‐Generation Probiotics: From Traditional Strains to Personalized Therapeutics
Jadhav, N. K., Magdum, A. B., Shinde, K. V., & Nimbalkar, M. S. (2026) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70339 · Cited by 29 · cited 1×
“NGPs have been linked to more specialized functions, including butyrate production, mucin degradation, increased intestinal barrier integrity, and modulation of host metabolism and inflammation [141].”
Bugs or drugs: Are probiotics safe for use in the critically ill?
Urben, L. M., Wiedmar, J., Boettcher, E., Cavallazzi, R., Martindale, R. G., & McClave, S. A. (2014) · Current Gastroenterology Reports · doi:10.1007/s11894-014-0388-y · Cited by 29
Conjugative DNA Transfer From E. coli to Transformation-Resistant Lactobacilli
Samperio, S., Guzmán-Herrador, D. L., May-Cuz, R., Martín, M. C., Álvarez, M. A., & Llosa, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.606629 · Cited by 25
Anadón, A., Martínez-Larrañaga, M. R., Ares, I., & Martínez, M. A. (2016) · Nutraceuticals · doi:10.1016/b978-0-12-802147-7.00055-3 · Cited by 24 · cited 2×
“In addition, probiotic microorganisms should not produce harmful substances during their metabolic activity [79].”
Casaro, M. B., Thomas, A. M., Mendes, E., Fukumori, C., Ribeiro, W. R., Oliveira, F. A., Crisma, A. R., Murata, G. M., Bizzarro, B., Sá-Nunes, A., et al. (2021) · Microbiome · doi:10.1186/s40168-021-01081-2 · Cited by 24 · cited 1×
“Accordingly, probiotic efficacy appears to be strain-and population-specific, with some strains being effective in certain patient groups but not in others [92,93], and there is evidence that probiotics may increase the risk of sensitization in individuals pre-disposed to allergic diseases [94].”
Harahap, I. A., Kuligowski, M., SCHMIDT, M. T., Kolodziejski, P. A., & Suliburska, J. (2023) · Food Science & Nutrition · doi:10.1002/fsn3.3571 · Cited by 22 · cited 1×
“It is also necessary to evaluate probiotics in view of their ambiguous impact on certain fairly large categories of the population, for example, as described for the effect on calcium, phosphorus and bone metabolism, magnesium status, lipid and blood profile in postmenopausal women [116–120].”
Probiotic based therapy for atopic dermatitis: Outcomes of clinical studies
Sivamaruthi, B., Kesika, P., & Chaiyasut, C. (2018) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/2221-1691.235328 · Cited by 22 · cited 1×
“Accordingly, probiotic efficacy appears to be strain-and population-specific, with some strains being effective in certain patient groups but not in others [92,93], and there is evidence that probiotics may increase the risk of sensitization in individuals pre-disposed to allergic diseases [94].”
Liu, B., Zhong, X., Liu, Z., Guan, X., Wang, Q., Qi, R., Zhou, X., & Huang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417570 · Cited by 21 · cited 2×
“…the probiotic strain using genomic methods to identify potential virulence factors, antibiotic resistance genes, and other pathogenicity factors [82,144], metabolic activity [75], immune responses in terms of stimulation or suppression, especially in vulnerable populations such as children or…”
Safety of Probiotics in Health and Disease
Daliri, E. B.-M., Lee, B. H., & Oh, D. H. (2019) · The Role of Functional Food Security in Global Health · doi:10.1016/b978-0-12-813148-0.00034-7 · Cited by 21 · cited 3×
“Many strains of Lactobacillus have natural resistance to antibiotics such as aminoglycosides, while Bifidobacterium is resistant to gentamicin, streptomycin, and mupirocin [85].”
InfluentialProbiotics can cause D-lactic acidosis and brain fogginess: Reply to Quigley et al
Rao, S. S. C., Yu, S., Tetangco, E. P., & Yan, Y. (2018) · Clinical and Translational Gastroenterology · doi:10.1038/s41424-018-0077-5 · Cited by 20 · cited 1×
“Additional risks arise from strain-specific metabolic activity, such as the production of D-lactate or biogenic amines, which justifies targeted biochemical screening during the development phase [64,65].”
Jo, D.-M., Ko, S.-C., Kim, K. W., Yang, D., Kim, J.-Y., Oh, G.-W., Choi, G., Lee, D.-S., Tabassum, N., Kim, Y.-M., et al. (2025) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2025.105309 · Cited by 20 · cited 1×
“For example, the high variability of biological datasets on different platforms for sequence determination causes problems with the reliability of the source data, which undoubtedly underestimates the accuracy of the AI model [154,172].”
Qin, G., Wang, D., Luo, K., Liu, Y., Xie, Y., Wang, M., Li, C., Fan, R., & Tian, X. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128179 · Cited by 20 · cited 1×
“In vitro tests should help identify antibiotic resistance, hemolytic activity, and other important strain parameters [145,146], whereas in vivo studies should be conducted using animal models with weakened immune systems to more accurately model potential risks in vulnerable populations [75,147].”
Health claim regulation of probiotics in the USA and the EU: Is there a middle way?
Hoffmann, D. E. (2013) · Beneficial Microbes · doi:10.3920/bm2012.0033 · Cited by 19 · cited 3×
“In contrast to the EU regulatory framework, the United States generally does not require pre-market approval for health claims, particularly for structure/function claims [57,58].”
Harahap, I. A., SCHMIDT, M. T., Pruszyńska‐Oszmałek, E., Sassek, M., & Suliburska, J. (2024) · Nutrients · doi:10.3390/nu16152524 · Cited by 19
Legislation of probiotic foods and supplements
Chieffi, D., Fanelli, F., & Fusco, V. (2022) · Probiotics for Human Nutrition in Health and Disease · doi:10.1016/b978-0-323-89908-6.00013-3 · Cited by 16
Probiotics, Prebiotics, Synbiotics and its Health Benefits
Thilagavathi, T. (2020) · International Journal of Current Microbiology and Applied Sciences · doi:10.20546/ijcmas.2020.911.061 · Cited by 14 · cited 1×
“The term “synbiotics” is used to refer to products that include both probiotics and prebiotics, in which the beneficial properties of bacteria are supported by components that stimulate the growth of these same bacteria (Table 1) [24].”
Antibiotic-Resistant Desulfovibrio Produces H2S from Supplements for Animal Farming
Karnachuk, O. V., Beletsky, A. V., Rakitin, A. L., Ikkert, O. P., Avakyan, M. R., Zyusman, V. S., Napilov, A., Mardanov, A. V., & Ravin, N. V. (2023) · Microorganisms · doi:10.3390/microorganisms11040838 · Cited by 13 · cited 1×
“The identification of mobile antimicrobial resistance genes and their potential impact on intestinal resistance also requires whole-genome sequencing and detailed characterization of antibiotic resistance genes [42,66–68].”
Self-citationGiesriegl, F., Mrazek, C., & Cadamuro, J. (2025) · Journal of Laboratory and Precision Medicine · doi:10.21037/jlpm-25-6 · Cited by 13 · cited 1×
“…deep learning models have potential in probiotic research, their acceptance by regulatory authorities is hampered by the lack of clarity in their performance, as uninterpretable predictions do not provide a clear link to biological processes and specific safety characteristics of strains [167,170].”
A comprehensive review of mathematical modeling in probiotic microencapsulation
Udo, T., Qin, Z., Jiao, Y., Singh, R. K., & Kong, F. (2025) · Food Engineering Reviews · doi:10.1007/s12393-025-09402-z · Cited by 13 · cited 2×
“An additional way to uncover the properties of a strain may be to develop mathematical models to predict the behavior and safety of probiotics in the gut [20,149].”
Lv, N., Wang, C., Zhou, H., Ma, X., Yu, X., & Ren, D. (2024) · Foods · doi:10.3390/foods13131979 · Cited by 12 · cited 1×
“…genes and virulence factors at the genomic level); and prediction based on a machine learning model with the identification of specific tRNAs that distinguish safe probiotics against dangerous intestinal pathogens, which helps to carry out screening at an early stage [156,165,166].”
Woźniak, A., Dorotkiewicz‐Jach, A., & Brzychczy‐Włoch, M. (2025) · Postępy Mikrobiologii - Advancements of Microbiology · doi:10.2478/am-2025-0013 · Cited by 12
Perinatal probiotic mixture and development of allergic sensitization up to 13 years of age
Peldan, P. S., Kukkonen, A. K., Savilahti, E., & Kuitunen, M. (2020) · International Archives of Allergy and Immunology · doi:10.1159/000504915 · Cited by 11 · cited 1×
“Accordingly, probiotic efficacy appears to be strain-and population-specific, with some strains being effective in certain patient groups but not in others [92,93], and there is evidence that probiotics may increase the risk of sensitization in individuals pre-disposed to allergic diseases [94].”
Probiotics in critically ill patients: An umbrella review
Mahmoodpoor, A., Sanaie, S., Naseri, A., & Seyedi-Sahebari, S. (2022) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24129 · Cited by 11
Porchia, L. M., Vazquez-Marroquin, G., Ochoa-Précoma, R., Pérez-Fuentes, R., & Gonzalez-Mejia, M. E. (2022) · European Journal of Clinical Nutrition · doi:10.1038/s41430-022-01135-0 · Cited by 10 · cited 1×
“Conclusions were not universally positive, and some studies even reported unexpected side effects [87,108].”
Microbiological quality of probiotic products
Zavišić, G., Ristić, S., Petković, B., Živkov-Šaponja, D., Jojić, N., & Janković, D. (2023) · Arhiv za farmaciju · doi:10.5937/arhfarm73-42160 · Cited by 9
Liu, W., Zhang, S., Dong, C., Lv, X., Zheng, X., Zhao, W., Jamali, M., Abedi, R., & Saedisomeolia, A. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-01002-2 · Cited by 9 · cited 1×
“Another analysis of 46 datasets found that probiotics reduced relapse rates versus placebo, though heterogeneity and data overlap limit broad claims [110].”
Liu, Y., Zheng, H., Wang, J., Xin, J., Wu, R., Zhang, J., Zhong, Z., Liu, H., Huang, Y., Fu, H., et al. (2025) · BMC Microbiology · doi:10.1186/s12866-025-04099-w · Cited by 9 · cited 1×
“Whole-genome sequencing-based genomic screening allows for the in silico detection of antibiotic resistance genes, virulence-associated factors, and mobile genetic elements, thus providing a basis for modern probiotic safety evaluation [20,133,155,156].”
Boyte, M.-E., Akhtar, N., Koshy, B., & Roe, A. L. (2025) · Journal of Dietary Supplements · doi:10.1080/19390211.2024.2314488 · Cited by 9 · cited 1×
“Additionally, it is important to consider the specific characteristics and properties of the probiotic strains [47,50,149], while ensuring the safety of all ingredients in the probiotic composition [47,125,150].”
Skrypnik, K., SCHMIDT, M. T., Olejnik‐Schmidt, A., Harahap, I. A., & Suliburska, J. (2024) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.13329 · Cited by 8
Premarket notifications of new dietary ingredients--a ten-year review.
McGuffin, M., & Young, A. L. (2004) · PubMed · Cited by 8
Rana, A., & Smriti (2026) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.70275 · Cited by 7 · cited 1×
“This restriction leads to cautious labeling and limited marketing [39,60].”
Probiotics, postbiotics and paraprobiotics
Корниенко, Е. А. (2022) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-205-9-240-250 · Cited by 7 · cited 4×
“However, similar to the previous groups, they are intended to have a beneficial effect on the host’s body and contain substances released because of the metabolic activity of microorganisms [7].”
InfluentialTribby, D., & Teter, V. (2023) · Springer eBooks · doi:10.1007/978-3-031-30019-6_8 · Cited by 6
Ho, Y.-H., Huang, Y.-T., Lu, Y.-C., Lee, S.-Y., Tsai, M.-F., Hung, S.-P., & Hsu, T.-Y. (2017) · The Journal of nutrition, health and aging · doi:10.1007/s12603-016-0818-7 · Cited by 6 · cited 1×
“In addition to increasing the risk of infection, probiotics may contribute to the development of a nonspecific immune response in humans [83,84].”
Influence of Daidzein, Tempeh, and Probiotics on Phosphorus Levels in the Postmenopausal Rat Model
Harahap, I. A., Skrypnik, K., Kolodziejski, P. A., & Suliburska, J. (2025) · International Journal for Vitamin and Nutrition Research · doi:10.31083/ijvnr46717 · Cited by 4
Structure-Based Deep Learning Framework for Modeling Human–Gut Bacterial Protein Interactions
Kiouri, D. P., Batsis, G. C., & Chasapis, C. T. (2025) · Proteomes · doi:10.3390/proteomes13010010 · Cited by 3 · cited 1×
“Host–microbe interaction modeling, using systems biology, metabolic network reconstruction, and in silico simulations, provides insight into potential functional impacts and strain-specific mechanisms, supporting hypothesis generation before clinical validation [158].”
Wang, Y., Tan, W., Li, X., Yang, G., Wang, Y., Liao, J., Lu, A., Zhang, G., Chen, K., Yang, L., et al. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1455735 · Cited by 2 · cited 1×
“To accurately assess AE levels, experts emphasize clarifying strain-specific effects, dose–response relationships, and optimal regimens in trials for evidence-based guidance [112,113].”
Harahap, I. A., Salem, O., Fahmi, R. L., Ahmed, N., Leciejewska, N., & Suliburska, J. (2025) · Nutrients · doi:10.3390/nu17182917 · Cited by 2 · cited 1×
“It is also necessary to evaluate probiotics in view of their ambiguous impact on certain fairly large categories of the population, for example, as described for the effect on calcium, phosphorus and bone metabolism, magnesium status, lipid and blood profile in postmenopausal women [116–120].”
Zhou, S., Yu, Y., Tian, J., Wang, X., Zeng, M., & Song, H. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1704508 · Cited by 2 · cited 2×
“In 10 randomized controlled trials (1630 patients) on bismuth-containing quadruple therapy for Helicobacter pylori, probiotics lowered AEs from 27.98% (controls) to 16.85% [112].”
InfluentialToxicology of Probiotics: Challenges and Future Prospects
Das, U., Mehra, R. K., Mandal, S., Ashique, S., Kumar, S., Farid, A., Hussain, A., Mishra, N., Faiyazuddin, M., & Taghizadeh-Hesary, F. (2025) · The Role of Probiotics in Cancer Management · doi:10.1201/9781003610748-12 · Cited by 1
Whelan, K., & Myers, C. (2009) · Proceedings of the Nutrition Society · doi:10.1017/s0029665109001451 · Cited by 1 · cited 1×
“In general, LBPs based on Lactobacillus and Bifidobacterium are safe for patients receiving enteral or parenteral nutrition [76].”
Lactobacillus species as probiotics: Isolation sources and health benefits
Khalifa (2022) · J. Pure Appl. Microbiol.
UnresolvedUnderstanding Probiotics, Prebiotics, Synbiotics, and Postbiotics: A Comprehensive Review of the Newest Definitions, Selected Strains and Products
(2025) · Adv. Microbiol.
UnresolvedFAO (2025, December 22). Probiotics in Food: Health and Nutritional Properties and Guidelines for Evaluation (Food and Agriculture Organization of the United Nations, Rome, 2006). Available online: https://openknowledge.fao.org/server/api/core/bitstreams/382476b3-4d54-4175-803f-2f26f3526256/content.
(n.d.)
UnresolvedFDA (2025, December 22). Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information, Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-clinical-trials-live-biotherapeutic-products-chemistry-manufacturing-a
(n.d.)
UnresolvedEuropean Pharmacopoeia Commission (2019). 3053E General monograph on live biotherapeutic products. Eur. Pharmacopoeia, 10.
(n.d.)
UnresolvedEuropean Pharmacopoeia Commission (2019). Microbiological examination of live biotherapeutic products: Test for specified microorganism (2.6.38). Eur. Pharmacopoeia, 9, 6301–6305.
(n.d.)
UnresolvedNCCIH (2025, December 22). Probiotics: Usefulness and Safety. NCCIH, Available online: https://www.nccih.nih.gov/health/probiotics-usefulness-and-safety.
(n.d.)
UnresolvedFDA (2025, December 22). Microorganisms & Microbial-Derived Ingredients Used in Food. FDA, 2018, Available online: https://www.fda.gov/food/generally-recognized-safe-gras/microorganisms-microbial-derived-ingredients-used-food-partial-list.
(n.d.)
Unresolved(2001). Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Off. J. L, 311, 0067–0128. Available online: https://eur-lex.europa.eu/eli/dir/2001/83/oj/eng.
(n.d.)
Unresolved(2015). Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods. Off. J. Eur. Union L, 327, 1–22. Available online: https://faolex.fao.org/docs/pdf/eur151053.pdf.
(n.d.)
UnresolvedISAPP (2025, December 22). ISAPP Position Statement on Minimum Criteria for Harmonizing Global Regulatory Approaches for Probiotics in Foods and Supplements. Available online: https://isappscience.org/wp-content/uploads/2018/10/summary-document-probiotics-criteria-ISAPP.pdf.
(n.d.)
Unresolved(2019). EDQM. The European Directorate for the Quality of Medicines & HealthCare—EDQM. Live biotherapeutic products for human use 3053 monograph. Europ. Pharmacopoeia, 9, 6522–6523.
(n.d.)
Unresolved(2025, December 22). Benefit-Risk Assessment in Drug Regulatory Decision-Making. FDA, 2018, Available online: https://www.fda.gov/files/about%20fda/published/Benefit-Risk-Assessment-in-Drug-Regulatory-Decision-Making.pdf.
(n.d.)
UnresolvedPremarket notifications of new dietary ingredients--a ten-year review
McGuffin (2004) · Food Drug Law J.
UnresolvedEuropean Commission (2006). Regulation
(n.d.)
Unresolved(EC) No. 1924/2006 of the European parliament and of the council of 20th December 2006 on nutrition and health claims made on foods. Off. J. Eur. Union L, 404, 9-25. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32006R1924.
(n.d.)
Unresolved(2025, December 22). General pharmacopoeial article “Probiotics” OFS.1.7.1.0008.15. State Pharmacopoeia of the Russian Federation XIV edition. Moscow, 2018. Available online: https://docs.rucml.ru/feml/pharma/v14/vol2/783/.
(n.d.)
UnresolvedWatson, R.R., and Preedy, V.R. (2015). Probiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion, Academic Press.
(n.d.)
UnresolvedA comprehensive review of metabolic syndrome and its role in cardiovascular disease and type 2 diabetes mellitus: Mechanisms, risk factors, and management
Dhondge (2024) · Cureus
UnresolvedInteragency Coordination Group on Antimicrobial Resistance (2025, December 22). No Time to Wait: Securing the Future from Drug-Resistant Infections. Report to the Secretary General of the United Nations. Available online: https://www.who.int/docs/default-source/documents/no-time-to-wait-securing-the
(n.d.)
UnresolvedArtificial Intelligence for Authorisation Processes: From Collecting to Connecting Data
Ohlmann (2024) · Int. Anim. Health J.
UnresolvedCARD 2020: Antibiotic resistome surveillance with the comprehensive antibiotic resistance database
Alcock (2020) · Nucleic Acids Res.
Unresolved(2025, December 22). Regulation (EU) 2024/1689 of the European Parliament and of the Council of 13 June 2024. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32024R1689.
(n.d.)
Unresolved
Cited by
Probiotic-fortified functional foods: integrating nutrient delivery and gut health benefits
Alsanie, S. A. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1815558 · Cited by 4
“Clinical studies suggest that effective doses generally range between 10 8 and 10 11 CFU/day, though optimal dosing varies by strain and indication (11).”
Carneiro, K. O., Alves, M. V., & Todorov, S. D. (2026) · Antonie van Leeuwenhoek · doi:10.1007/s10482-026-02335-5 · Cited by 3
“( 1234567890) and increased attention can be explained by the numerous interactions with the environment, the development of antimicrobial resistance (antibiotics and biocides), genetic alterations, and mutations (Churin et al. 2026).”
Chong, S. Y., Raja‐Razali, R. B., Ismail, N. H., Ushidee-Radzi, M. A., Zahia-Azizan, N. A., Manickam, M., Norhisham, D. ‘., Ilham, Z., Reale, A., Nazzaro, S., et al. (2026) · Foods · doi:10.3390/foods15122079 · Cited by 2
“The safety evaluation of probiotic LAB frequently involves an examination of hemolytic activity, antibiotic resistance patterns, pathogenic potential, and metabolic by-products [355].”
Purohit, H. V., Chakraborty, J., Kothari, R. K., & Bhatt, A. R. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-11029-3 · Cited by 3
Predicting Host-Interaction Traits in Probiotic Bacteria Using Machine Learning and Functional Data
da Luz, G. D. Q., Kappel, K. S., Dias, R. S., Leite, F. P. L., & Kremer, F. S. (2026) · Journal of Genome Biotechnology and Genetics · doi:10.3390/jgbg1020012 · Cited by 1
“However, genomic analysis based solely on sequence alignments and homology does not capture higher-order interactions among genomic components [8].”
Metadata
- Authors
- Churin, A. A., Sokolyanskaya, L. O., Lukina, A. P., & Karnachuk, O. V.
- Affiliations
- National Research Tomsk State University (RU)
- Corresponding author
- Churin, Alexey A.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2026-02-21
- Volume
- 18
- Issue
- 4
- Pages
- 696
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC12942808
- OpenAlex
- W7130931644
- Cited by
- 31
- References
- 175
- Citations by year
- 2026: 31
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Russian Science Foundation (25-24-00493)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- probiotics, probiotic safety, probiotic efficacy, adverse events, probiotic regulation, live biotherapeutic products, dietary supplements, safety assessment, microbiome
- MeSH terms
- Humans, Dietary Supplements, Probiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.